Egis Gyogyszergyar Rt.

Egis Gyogyszergyar

Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag

Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag

Egis Gyogyszergyar Nyilvanosan Muekoedoe

Egis Gyogyszergynar Nyilvanosan Muekoedoe Reszvenytarsasag

Kalman Nagy

Gyula Simig

Jozsef Barkoczy

Ferenc Lorant Bartha

Balazs Volk

Gyorgy Krasznai

Janos Imre

Attila Mandi

Daniel Bozsing

Peter Tompe

Adrienn Keszthelyi

Eva Furdyga

Gyoergy Ruzsics

Gabor Kovacs

Imre Moravcsik

Pal Benko

Antal Simay

Gabor Blasko

Frigyes Gorgenyi

Zoltan Zubovics

Istvan Simonyi

Ivan Beck

Laszlo Levai

Eva Sipos

Ferenc Szederkenyi

Lajos Toldi

Eva J Tajthy Nee Juhasz

Eva Kovacs Nee Bozo

Gyorgyi Vereczkey Nee Donath

Gabor Feher

Gyorgyi Kovanyi Nee Lax

Zsuzsa Szent Kirallyi

Erzsebet Kiss Nee Bertok

Peter Kotay Nagy

Gyorgy Mikite

Ilona Dinnyes Nee Nagy

Eva Poczik

Norbert Nemeth

Gyorgyi Zalavari Nee Dosa

Gyoergyi Kovanyine Lax

Tibor Mezei

Zoltan Budai

Laszlo Balazs

Gabor Nemeth

Jozsef Reiter

Imre Klebovich

Klara Reiter Nee Esses

Laszlo Pongo

Pal Vago

Margit Csorgo

Andras Dancso

Gyorgy Ruzsics

Gyorgyi Kovanyine Lax

Imre Kiraly

Peter Seres

Gyoergy Clementis

Judit Broda

Ilona Sztruhar

Peter Slegel

Jozsef Debreczeni

Zoltan Ratkai

Imre Doman

Judit Szego

Gyongyi Vereczkey Nee Donath

Laszlo Koncz

Gyorgyi Donath Vereczkey

Gabor Nemei

Gyorgyi Lax Kovanyi

Gyorgyi Vereczkeyne Donath

Ferenc Barta

Peter Tömpe

Gyōrgy Clementis

Gyōrgyi Vereczkeyne Donath

Györgyi Vereczkeyne Donath

Adrienn Karasz

Imre Koehegyi

Valeria Hoffmanne Fekete

Gyoergy Krasznai

Gyoergy Morovjan

Gabor Bagyinszki

Gyorgy Morovjan

The present invention is related to intermediates useful in the preparation of pharmaceutically acceptable salts of (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-(3R,5S)-dihydroxy-hept-6-enoic acid and polymorphs of said intermediates, methods for preparation thereof and use thereof.

Method for the preparation of high-purity pharmaceutical intermediates

The present invention relates to crystalline Form I rosuvastatin zinc (2:1) salt, method of preparation thereof and use thereof as pharmaceutically active ingredient for the treatment of diseases related to lipid metabolism including hyperlipoproteinemia, hypercholesteremia, dyslipidemia and atherosclerosis.

Crystalline form I rosuvastatin zinc salt

The present invention relates to the use of novel vildagliptin complexes for the manufacture of high purity vildagliptin of Formula I and/or pharmaceutical acceptable salts thereof. Further objects of the present invention are pharmaceutically acceptable complexes of vildagliptin and/or amorphous and crystalline forms, anhydrous forms, amorphous and crystalline hydrates, amorphous and crystalline solvates of the complexes and a process for the preparation thereof. Another object of the present invention is the high purity vildagliptin and pharmaceutically acceptable salts thereof prepared form the vildagliptin complexes of the present invention, a process for the preparation thereof and pharmaceutical compositions containing vildagliptin base, pharmaceutically acceptable salts and/or complexes and use thereof for the treatment of type 2 diabetes (NIDDM). The present invention provides pharmaceutically advantageous high purity vildagliptin complexes.

Inorganic salt complexes of vildagliptin

The present invention relates to a new process for the preparation of rosuvastatin [7-[4-(4-Fluorophenyl)-6-isopropyl-2-(methanesulphonyl-methyl-amino)-pyrimidin-5-yl]-(3R,51S)-dihydroxy-hept-6-enoic acid] of the formula (I) salts formed with bivalent cations, preferably with calcium or zinc ions, characterized in that rosuvastatin tert.-butylammonium salt is reacted with the appropriate bivalent cation, preferably with calcium or zinc ions in a mixture of a water immiscible or slightly miscible organic solvent and water and the formed salt is isolated. 

Process for the preparation of rosuvastatin salts

The invention relates to new crystalline forms I and II of (4R-cis)-6-[2-[3-phenyl-4-(phenyl-carbamoyl)-2-(4-fluoro-phenyl)-5-(1- methyl-ethyl)-pyrrol-1-yl]-ethyl]-2,2-dimethyl-[1,3]dioxane-4-yl-acetic acid-tertiary butyl ester of the Formula (I) and a process for the preparation thereof. The new polymorphs of the present invention are useful pharmaceutical intermediates which can be used in the preparation of the hydroxymethyl-glutaryl coenzyme (HMG-COA) reducing enzyme inhibitor having the INN (International Non-proprietory Name) atorvastatin 

Polymorphs of a 1-pyrrole derivative, intermediate for the preparation of atorvastatin

The invention refers to a novel process for the preparation of {2-[-(&#x3b1;-phenyl-p-chlorobenzyl)piperazin-1-yl]ethoxy}acetic acid, which comprises hydrolyzing an N,N-disubstituted {2-[-(&#x3b1;-phenyl-p-chlorobenzyl)piperazin-1-yl]ethoxy}acetamide, wherein said substituents are selected from alkyl groups having 1 to 4 carbon atoms optionally substituted by a phenyl group, alkenyl groups having 2 to 4 carbon atoms or cyclohexyl groups, or the substituents together with the adjacent nitrogen atom of the acetoamido group, form a morpholino group.

Process for the preparation of {2-[4-&#x3b1;-phenyl-p-chlorobenzyl)piperazin-1-yl]ethoxy} acetic acid and novel intermediates therefor

The invention relates to a process for the preparation of amorphous atorvastatin calcium by recrystallization of crude atorvastatin from an organic solvent which comprises dissolving crude amorphous atorvastatin calcium in a lower alkanol containing 2-4 carbon atoms or a mixture of such alkanols under heating and isolating the amorphous atorvastatin calcium precipitated after cooling. The atorvastatin calcium obtained is a known valuable agent useful in treating hyperlipidemia and hypercholestrolemia.

Process for the preparation of amorphous atorvastatin calcium

The invention relates to a new process for the preparation of amlodipine besylate of the Formula ##STR1## Amlodipine besylate of the Formula I is a valuable known blood pressure decreasing antianginal agent. The advantage of the process of the present invention is that it can be carried out in a simple way with high yields and there is no need to isolate the amlodipine base.

Process for the preparation of a dihydropyridine derivative

Process for the preparation of 8 -[4 -[4-(pyrimidine-2-yl)-piperazine-1-yl]-butyl]-8-aza-spiro[4.5]decane-7,9-d ione (buspiron) of the Formula I ##STR1## and the hydrochlorides thereof having high purity by continuously adding a solution of 8-[4-[4-(pyrimidine-2-yl)-piperazine-1-yl]-but-2 -inyl]-8-aza-spiro[4.5]decane-7,9-dione of the formula II ##STR2## formed with an inert organic solvent having a concentration of at least 40% by weight to a suspension of a hydrogenation catalyst in an inert organic solvent and optionally converting the 8-[4-[4-(pyrimidine-2-yl)-piperazine-1-yl]-butyl]-8-aza-spiro[4.5]decane-7 ,9-dione thus obtained into the hydrochloride thereof.

Process for the preparation of high purity buspiron and the

The invention relates to an improved process for the preparation of 2,2-dimethyl-5-(2,5-dimethylphenoxy)-pentanoic acid of Formula (I) ##STR1## which comprises reacting an ester of the general Formula (X) ##STR2## wherein X represents halogen and Z stands for a straight or branched chain C.sub.1-8 alkylene group optionally substituted by one or two 2,2-dimethyl-5-halopentanoyloxy group(s), wherein halo represents chlorine or bromine, and in which alkylene group one or two methylene group(s) may be optionally replaced either by hetero atom(s) or by a bivalent heterocyclic group--with an alkali salt of 2,5-dimethylphenol of Formula (II) ##STR3## or with an ester of the latter formed with a lower alkanoic acid, and hydrolizing the aryloxy-substituted ester of the general Formula (XI) thus obtained. ##STR4## Furthermore the invention relates to intermediate compounds of the general Formula (X), wherein X and Z are as stated above, and to a process for the preparation thereof.

Process for the preparation of

The invention relates to a process for the preparation of dimethyl-1,4-dihydro-2,6-dimethyl-4-(2'-nitro-phenyl)-pyridine-3,5-dicarbo xylate of the Formula I ##STR1## which comprises a) reacting a compound of the general Formula II ##STR2## (wherein n is 1 or 3; if n is 1, then R stands for a group of the Formula (a) ##STR3## and if n is 3, then R represents hydrogen) with methyl acetoacetate of the Formula III

1,4,Dihydro-pyridine intermediates

The invention relates to an improved process for the preparation of 2,2-dimethyl-5-(2,5-dimethylphenoxy)-pentanoic acid of Formula (I) ##STR1## which comprises reacting an ester of the general Formula (X) ##STR2## wherein X represents halogen and Z stands for a straight or branched chain C.sub.1-8 alkylene group optionally substituted by one or two 2,2-dimethyl-5-halopentanoyloxy group(s), wherein halo represents chlorine or bromine, and in which alkylene group one or two methylene group(s) may be optionally replaced either by hetero atom(s) or by a bivalent heterocyclic group--with an alkali salt of 2,5-dimethylphenol of Formula (II) ##STR3## or with an ester of the latter formed with a lower alkanoic acid, and hydrolizing the aryloxy-substituted ester of the general Formula (XI) thus obtained. Furthermore the invention relates to intermediate compounds of the general Formula (X), wherein X and Z are as stated above, and to a process for the preparation thereof.

The invention is directed to processes for the preparation of dimethyl-1,4-dihydro-2,6-dimethyl-4-(2'-nitrophenyl)-pyridine-3,5-dicarbox ylate by reacting 1-methoxy-1-(2'-nitrophenyl)-N-(2'-nitrophenyl)methylene methanamie or 1-(2'-nitrophenyl)-N,N'-bis-(2'-nitrophenyl) methylene methanediamine with methyl acetoacetate in the presence of an amine compound or by reacting the monomeric or trimeric from of 2-nitrobenzaldimine with methyl acetoacetate.

Process for the preparation of 1,4-dihydro-pyridine derivatives

Growing community of inventors

Budapest, Hungary

Kalman Nagy